Search

We request that the following corrections be made in our article. [ABSTRACT FROM AUTHOR]

Purpose of Review: Heart failure (HF) management guided by hemodynamics obtained from an implantable pulmonary artery pressure (PAP) sensor (CardioMEMS) improves symptoms and reduces HF hospitalizations (HFH). This paper reviews the theoretical basis of pulmonary vascular physiology, summarizes recently published data about CardioMEMS, and provides practical guidelines for patient selection and management. Recent Findings: Compared to patients managed by standard care, HF patients randomized to PAP-guided treatment have a higher frequency of medication adjustments, resulting in lower PAP and fewer HFH. Real-world analyses further support associations between implant of the CardioMEMS sensor with reductions in PAP, hospitalizations, and mortality. Summary: Implantable, wireless hemodynamic sensor technology is a promising remote monitoring platform for chronic HF. A phased approach using a treatment algorithm may improve the efficiency and effectiveness of pressure-guided therapy. [ABSTRACT FROM AUTHOR]

Background: Hemodynamic Frontiers in Heart Failure (HF 2 ) is a multicenter academic research consortium comprised of 14 US institutions with mature remote monitoring programs for ambulatory patients with heart failure (HF). The consortium developed a retrospective and prospective registry of patients implanted with a wireless pulmonary artery pressure (PAP) sensor., Goals/aims: HF 2 registry collects demographic, clinical, laboratory, echocardiographic (ECHO), and hemodynamic data from patients with PAP sensors. The aims of HF 2 are to advance understanding of HF and to accelerate development of novel diagnostic and therapeutic innovations., Methods: HF 2 includes adult patients implanted with a PAP sensor as per FDA indications (New York Heart Association (NYHA) Class III HF functional class with a prior hospitalization, or patients with NYHA Class II or brain natriuretic peptide (BNP) elevation without hospitalization) at a HF 2 member site between 1/1/19 to present. HF 2 registry is maintained at University of Kansas Medical Center (KUMC). The registry was approved by the institutional review board (IRB) at all participating institutions with required data use agreements. Institutions report data into the electronic registry database using REDCap, housed at KUMC., Results: This initial data set includes 254 patients implanted from the start of 2019 until May 2023. At time of device implant, the cohort average age is 73 years old, 59.8% are male, 72% have NYHA Class III HF, 40% have left ventricular ejection fraction (LVEF) < 40%, 35% have LVEF > 50%, mean BNP is 560 pg/ml, mean N-Terminal pro-BNP (NTproBNP) is 5,490 pg/ml, mean creatinine is 1.65 mg/dl. Average baseline hemodynamics at device implant are right atrial pressure (RAP) of 11 mmHg, pulmonary artery systolic pressure (PASP) of 47 mmHg, pulmonary artery diastolic pressure (PADP) 21 mmHg, mean pulmonary artery pressure (mPAP) of 20 mmHg, pulmonary capillary wedge pressure (PCWP) of 19 mmHg, cardiac output (CO) of 5.3 L/min, and cardiac index (CI) of 2.5 L/min/m 2 ., Conclusion: A real-world registry of patients implanted with a PAP sensor enables long-term evaluation of hemodynamic and clinic outcomes in highly-phenotyped ambulatory HF patients, and creates a unique opportunity to validate and test novel diagnostic and therapeutic approaches to HF., Competing Interests: TH received honoraria from Johnson and Johnson, United Therapeutics, Boehringer Ingelheim, Bayer, Lily as well as research grant support from Johnson and Johnson. JA is a consultant for Abiomed and Abbott, and is on the speaker's bureau for Abiomed, Abbott, Ancora. MF is a speaker for Abbott. AS disclosures include consulting for or receiving research funding from Abbott, Boston Scientific, Medtronic, Biotronik, Impulse Dynamics, Acorai, General Prognostics, Edwards Lifesciences, Story Health, Bayer, CSL Vifor. HS is a consultant for Endotronix and a speaker for Impulse Dynamics. AB is a consultant for Abbott. PM is a consultant for Abbott, AstraZeneca, Janssen, Daxor, and CVRx. OJ is a speaker for Abbott. KB is on the speaker's bureau for Abbott, Pfizer, and Novartis and is a consultant for Abbott and Vectorius. MB is a consultant for Abbott and Rhythm Management Group. TAB is a consultant for Abbott. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Heywood, Munshi, Jordan, Muse, Fudim, Sauer, McDermott, Shah, Bhimaraj, Khedraki, Robinson, McCann, Volz, Guha, Jonsson, Bhatt, Bennett, Benjamin, Guglin and Abraham.)